A participant who died during aAstraZeneca Plc’s Covid-19 vaccine in Brazil had not received the company’s vaccine, according to a person familiar with the matter.
The person has asked not to be identified because the information is not public.
Brazilian health authority Anvisa said it was informed on Monday of the death of the study volunteer and received a partial report from an international committee evaluating the safety of the trial. This committee suggested that the trial continue, Anvisa said in a statement.
AstraZeneca, which is developing the vaccine with the University of Oxford, said it could not comment on individual cases due to privacy rules and clinical trials. Oxford has no concerns about the safety of the vaccine trial after careful independent review, and Brazilian regulators have recommended that it continue, University communications officer Stephen Rouse said in a report. communicated.
AstraZeneca’s U.S. certificates of deposit fell 3.3% in New York on Wednesday afternoon after the person’s death was announced, but reduced most of those losses in recent trades.
Trial break in the United States
A clinical trial of the vaccine in the United States has been on hold sincemore than a month. Studies were halted around the world in September when a British participant fell ill, but have resumed in the UK, Brazil, South Africa and India in recent weeks. While temporary breaks in vaccine studies are common, AstraZeneca and Oxford have faced pressure to disclose more information about the UK episode.
The halt to the US trial raised concerns about the prospects for one of the fastest shots in the world and highlighted the hurdles researchers face when developing a vaccine. Another vaccine manufacturer, Johnson & Johnson,said earlier this month he would put his trial on hold to investigate a disease in a study participant.
The AstraZeneca and J&J vaccines are both based on adenoviruses, common cold germs that researchers have used in experimental therapies for decades, and the two discontinued trials haveraised questions about the approach.
AstraZenecatold analysts in early October that he expected the US study to resume this year and that global approval would be determined by test results outside the United States.
– With the help of Riley Griffin
(Updates with Brazilian health authority comment in third paragraph, Oxford commentary in fourth.)